Use of aStaphylococcus aureusConjugate Vaccine in Patients Receiving Hemodialysis
Top Cited Papers
- 14 February 2002
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 346 (7), 491-496
- https://doi.org/10.1056/nejmoa011297
Abstract
In patients with decreased resistance to infection, Staphylococcus aureus is a major cause of bacteremia and its complications. The capsular polysaccharides are essential for the pathogenesis of and immunity to S. aureus infection and are targets for vaccines.Keywords
This publication has 29 references indexed in Scilit:
- Staphylococcus aureusBacteremia — Consider the SourceNew England Journal of Medicine, 2001
- Methicillin-ResistantStaphylococcus aureusin the Community: A Hospital-Based StudyInfection Control & Hospital Epidemiology, 1999
- Nosocomial infections in medical intensive care units in the United StatesCritical Care Medicine, 1999
- Emergence of Vancomycin Resistance inStaphylococcus aureusNew England Journal of Medicine, 1999
- The Economic Impact ofStaphylococcus aureusInfection in New York City HospitalsEmerging Infectious Diseases, 1999
- Staphylococcus aureusInfectionsNew England Journal of Medicine, 1998
- Prevention of Systemic Infections Caused by Group B Streptococcus and Staphylococcus aureus by Multivalent Polysaccharide‐Protein Conjugate VaccinesAnnals of the New York Academy of Sciences, 1995
- Bacteremia in Patients on Chronic HemodialysisNephron, 1993
- Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureusDiagnostic Microbiology and Infectious Disease, 1984
- Quantitative Measurement of “Natural” and Immunization-induced Haemophilus influenzas type b Capsular Polysaccharide AntibodiesPediatric Research, 1973